Brenda Khan
Fen-phen, a combination of fenfluramine and phentermine, was an anti-obesity medication that gained rapid popularity in the 1990s. Marketed as a miracle weight-loss drug, it was prescribed off-label as a combination treatment despite never being approved by the FDA for this use. Fen-phen was eventually pulled from the market in 1997 due to serious side effects, including heart valve damage and pulmonary hypertension, which led to a wave of lawsuits and settlements for injured patients. Phentermine, one of the components of fen-phen, is still used today in combination with topiramate to aid weight loss, but it is a controlled substance that can have side effects such as a fast heart rate, high blood pressure, and sleep disturbances.
| Characteristics | Values |
|---|---|
| Brand Name | Fen-Phen |
| Generic Name | Fenfluramine/Phentermine |
| Drug Class | Appetite Suppressant |
| Drug Type | Anti-obesity medication |
| Dosage Form | Extended-release capsules |
| Administration Route | Oral |
| Frequency | Once daily |
| Special Precautions | Store at room temperature, keep out of reach of children |
| Side Effects | Fast heart rate, high blood pressure, trouble sleeping, dizziness, restlessness, valvular heart disease, pulmonary hypertension |
| Black Box Warnings | Risk of cardiac valvular disease |
| Lawsuits | Over 50,000 product liability lawsuits, total liability estimated at $14 billion |
| Availability | No longer widely available |
Explore related products
What You'll Learn
Fen-phen is a combination of fenfluramine and phentermine
Fen-phen is the popular name given to the combination of appetite suppressants fenfluramine and phentermine. It was used to treat patients with severe obesity problems and was even used as a way to fight some drug and alcohol addictions. While the FDA approved fenfluramine and phentermine for separate use, the agency never approved them to be used in combination with one another. Even without FDA approval, Fen-phen gained immense popularity as a wonder drug that could help people lose weight faster than diet and exercise.
Fen-phen was first introduced in the 1970s as a standalone drug, but it was not popular because it only temporarily reduced weight, and patients complained of nausea, anxiety, and other uncomfortable side effects. In 1992, a research team led by Dr. Michael Weintraub of the University of Rochester claimed that the combination of fenfluramine and phentermine was more effective in treating obesity without causing the annoying side effects of previous diet drugs. This combination of weight loss drugs received massive amounts of media attention and quickly became known as the miracle medicine "Fen-phen".
Fen-phen's popularity skyrocketed, but its manufacturer, American Home Products (later known as Wyeth), was concerned. In 1996, a 30-year-old woman developed heart problems after a month of using fen-phen; when she died in February 1997, the Boston Herald devoted a front-page article to her. In August 1997, a paper in the New England Journal of Medicine (NEJM) from the Mayo Clinic discussed clinical findings in 24 people who had taken fen-phen. The authors noted that their findings suggested a possible correlation between mitral valve dysfunction and the use of these anorectic agents.
In September 1997, the FDA requested the withdrawal of fen-phen from the market. This action was based on findings from doctors who had evaluated people taking these two drugs with echocardiograms, a procedure that can test the functioning of heart valves. The findings indicated that approximately 30% of people who had taken the combination for up to 24 months had abnormal echocardiograms, even though they had no symptoms. This percentage of abnormal test results was much higher than would be expected from a sample of the population who had not been exposed to either fenfluramine or dexfenfluramine. Follow-up studies showed that for people who took the combination for 3 months or less, the rate of heart valve complications was less than 3%.
Sugar: Friend or Foe in Your Diet?
You may want to see also
Explore related products
Fen-phen was used to treat severe obesity
Fen-phen was a combination of fenfluramine and phentermine, two appetite-suppressing drugs. Fenfluramine was first introduced in the 1970s as a treatment for obesity, but it proved unpopular due to its temporary effects and uncomfortable side effects, including nausea and anxiety.
In 1992, a research team led by Dr. Michael Weintraub found that the combination of fenfluramine and phentermine was more effective in treating obesity without causing the same side effects as previous diet drugs. This combination treatment gained immense popularity as a "miracle" weight-loss drug, despite never being approved by the FDA.
However, in the mid-1990s, concerns began to arise about the safety of fen-phen. Reports emerged of individuals, particularly women, who had developed severe heart valve damage and pulmonary hypertension after taking the drug combination. This led to an investigation by the FDA, which ultimately requested the withdrawal of fenfluramine and dexfenfluramine from the market in September 1997. The FDA's action was based on findings that approximately 30% of individuals who had taken the combination for up to 24 months had abnormal echocardiograms, indicating heart valve problems.
Vegetarian Diet: Avoid These Sugars for Better Health
You may want to see also
Explore related products
Fen-phen was never approved by the FDA
Fen-phen, a combination of fenfluramine and phentermine, was a popular weight-loss drug in the 1990s. Despite its popularity, fen-phen was never approved by the FDA for several reasons.
Firstly, fen-phen was not adequately tested for safety. The drug manufacturer, American Home Products, was more focused on obtaining FDA approval for the sale of dexfenfluramine, a new version of fenfluramine, than ensuring the drug combination's safety. As a result, fen-phen entered the market without sufficient safety data.
Secondly, fen-phen was associated with serious side effects, including heart valve damage and pulmonary hypertension. In 1997, two separate studies published in the New England Journal of Medicine (NEJM) linked fen-phen to severe cardiac problems, including heart disease, cardiac valvular disease, and cardiac fibrosis. These studies revealed that approximately one in three people exposed to fen-phen showed signs of abnormal heart issues, even though they exhibited no symptoms. The FDA's subsequent request for healthcare professionals to report similar cases yielded over a hundred additional reports of valvular heart disease related to fen-phen usage.
The FDA took action in response to these findings, requesting the withdrawal of fen-phen and related drugs from the market in September 1997. The agency's Lead Deputy Commissioner, Dr. Michael A. Friedman, acknowledged the unacceptable risk posed by fen-phen and dexfenfluramine to patients, emphasizing the need for prompt action.
The lack of FDA approval for fen-phen underscores the importance of rigorous testing and evaluation before a drug can be deemed safe for consumer use. While short-term weight loss may be achieved, the potential for severe and even life-threatening side effects cannot be overlooked. The fen-phen case highlights the critical role of regulatory agencies like the FDA in safeguarding public health and protecting consumers from potentially harmful products.
Can Diet Influence Genetic Disorders in Dogs?
You may want to see also
Explore related products
Fen-phen was linked to severe heart and lung damage
Fen-phen, a combination of fenfluramine and phentermine, was a popular anti-obesity medication in the early 1990s. While it delivered on its weight-loss promise, it also led to severe and sometimes fatal side effects, particularly related to heart and lung function.
The drug combination was found to cause pulmonary hypertension and heart valve problems. Pulmonary hypertension is high blood pressure that affects the veins in the heart and lungs, and it can lead to shortness of breath, swelling of the feet, and chest pain. A French study in 1996 found that using fenfluramine increased the risk of pulmonary hypertension, especially for those taking the drug for more than three months.
In 1996, a 30-year-old woman developed heart problems after taking fen-phen for a month. Unfortunately, she passed away in February 1997, and her story made the front page of the Boston Herald. This tragic incident brought further attention to the potential dangers of fen-phen.
A key Mayo Clinic study, published in the New England Journal of Medicine in 1997, examined the health of 24 women taking fen-phen. Despite having no prior history of heart disease, eight of these women developed pulmonary hypertension, and all 24 showed significant heart valve damage. At least five required heart surgery. This study prompted the FDA to alert medical practitioners about the risks associated with fen-phen.
The FDA received over a hundred additional reports of valvular heart disease in people taking fen-phen, fenfluramine alone, or dexfenfluramine alone. In 1997, the FDA withdrew approval of both fenfluramine and dexfenfluramine, acknowledging the unacceptable risks these drugs presented to patients.
Healthy Eating: Why Dieting is Important
You may want to see also
Explore related products
Fen-phen was pulled from the market in 1997
Fen-phen, a combination of fenfluramine and phentermine, was a popular weight-loss drug in the 1990s. Despite not being approved by the FDA, it was heavily marketed as a "miracle" or "wonder drug" and gained rapid popularity. However, in 1997, it was pulled from the market due to serious health concerns and side effects.
The decision to withdraw fen-phen was made in response to mounting evidence of its harmful impact on heart valves and pulmonary hypertension. The FDA received numerous reports of valvular heart disease and pulmonary hypertension, primarily in women who had been using fen-phen or dexfenfluramine. Follow-up studies revealed that approximately 30% of individuals who had taken the drug combination for up to 24 months exhibited abnormal echocardiograms, indicating heart valve complications. This rate was significantly higher than expected compared to individuals who had not been exposed to these drugs.
The FDA's request for the withdrawal of fen-phen from the market was based on the findings of doctors who utilised echocardiograms to evaluate individuals taking these medications. The manufacturers of fenfluramine and dexfenfluramine were asked to stop distributing the drugs, and the FDA issued a warning about the unacceptable risks associated with their use. The agency also recommended a black box warning for phentermine, highlighting the risk of cardiac valvular disease when used in combination with fenfluramine or dexfenfluramine.
The revelation of fen-phen's dangers sparked a wave of lawsuits and product liability claims against the drug's manufacturer, Wyeth (formerly known as American Home Products). By 2005, over 50,000 lawsuits had been filed, with total liability estimated at $14 billion. Wyeth set aside $21.1 billion to cover the cost of settlements and negotiations. The fallout from the fen-phen scandal highlighted the shortcomings of drug safety evaluation and the aggressive marketing of weight-loss drugs despite limited testing and unknown long-term effects.
Boosting Iodine Intake: Simple Dietary Strategies and Solutions
You may want to see also
Frequently asked questions
Fen-Phen is the popular name given to the combination of appetite suppressants fenfluramine and phentermine.
Fen-Phen is used to treat patients with severe obesity problems and has even been used as a way to fight some drug and alcohol addictions.
Fen-Phen has been linked to severe heart and lung damage, including valvular heart disease and pulmonary hypertension. Other side effects of phentermine include a fast heart rate, high blood pressure, trouble sleeping, dizziness, and restlessness.
Fen-Phen is no longer widely available. It was removed from the market in 1997 after concerns about its side effects.
There have been thousands of product liability lawsuits filed by alleged Fen-Phen victims, with total liability estimated to be as high as $14 billion.
